Nephron 1992:61:276-277
11 Renal Unit, I.N.R.C.A., Turin; b Institute of Nephro-Urology and d Institute of Genetics, University of Turin: c Division of Gastroenterology, S. Giovanni-Molinette Hospital, Turin, Italy
................................................................ K e y W o rd s
Hepatitis Kidney transplantation Anti-HCV antibodies 1nfections
Antibodies to Hepatitis C Virus in Kidney Transplantation
...............................................................................................................................................................
Abstract
Ninety patients on dialysis, 241 cadaveric kidney donors and 27 cadaveric kidney recipients with a follow-up of 2 years, have been investigated as for anti-HCV positivity by means of 3 tests. As for patients on dialysis and cadaveric donors, the prevalence was 32 and 4%, respectively. As for transplanted patients, it must be noted that 4 negative recipients from positive donors seroconverted. but without any change in hepatic enzymes, while in 2 or 9 anti-HCV-positive recipients, hepatic enzymes increased after transplantation. Seroconversion in patients transplanted from a negative donor was not significantly different. We conclude that, according to their experience, anti-HCV positivity in the donors is not associated with a significant risk of infection in recipients of cadaveric grafts.
Introduction
In a previous study [1], classic HCV makers were investi gated by conventional techniques (Ortho-HCV ELISA) using antibodies (Ab) against a recombinant antigen (Ag, 000-3). More recent tests, C 22, C 200 Ags (Ortho), C 22, C 33-c and C 100 (Abbott) and Western blot against C 22, C 33, 5-1-1 and C 100 (Riba-Ortho) were introduced [2]and used to further extend our data.
Material and M ethods Our study was performed retrospectively with 3 methodologies on sera from 90 patients on the waiting list, 241 cadaver donors (from May 1984 to December 1990), and 27 recipients. Recipients were monitored after transplantation for a period of 2 years with detection of anti-HCV Ab and transaminases.
Results
The prevalence of anti-HCV Ab was 32% in urémies on the waiting list. No difference was found in age (40.8 ± 12.8 years in anti-HCV-negative versus 37.3 ±13.5 in antiHCV-positive patients), M /F ratio (33/28 versus 19/10), blood units (all types of blood; 7.4± 14.2 versus 10.5 ± 15.3), provenance of kidneys (regional in 54/61 ver sus 26/29), whereas dialytic age (49.8 ±36.2 versus 96.8± 42.1 months, p
11 Renal Unit, I.N.R.C.A., Turin; b Institute of Nephro-Urology and d Institute of Genetics, University of Turin: c Division of Gastroenterology, S. Giovanni-Molinette Hospital, Turin, Italy
................................................................ K e y W o rd s
Hepatitis Kidney transplantation Anti-HCV antibodies 1nfections
Antibodies to Hepatitis C Virus in Kidney Transplantation
...............................................................................................................................................................
Abstract
Ninety patients on dialysis, 241 cadaveric kidney donors and 27 cadaveric kidney recipients with a follow-up of 2 years, have been investigated as for anti-HCV positivity by means of 3 tests. As for patients on dialysis and cadaveric donors, the prevalence was 32 and 4%, respectively. As for transplanted patients, it must be noted that 4 negative recipients from positive donors seroconverted. but without any change in hepatic enzymes, while in 2 or 9 anti-HCV-positive recipients, hepatic enzymes increased after transplantation. Seroconversion in patients transplanted from a negative donor was not significantly different. We conclude that, according to their experience, anti-HCV positivity in the donors is not associated with a significant risk of infection in recipients of cadaveric grafts.
Introduction
In a previous study [1], classic HCV makers were investi gated by conventional techniques (Ortho-HCV ELISA) using antibodies (Ab) against a recombinant antigen (Ag, 000-3). More recent tests, C 22, C 200 Ags (Ortho), C 22, C 33-c and C 100 (Abbott) and Western blot against C 22, C 33, 5-1-1 and C 100 (Riba-Ortho) were introduced [2]and used to further extend our data.
Material and M ethods Our study was performed retrospectively with 3 methodologies on sera from 90 patients on the waiting list, 241 cadaver donors (from May 1984 to December 1990), and 27 recipients. Recipients were monitored after transplantation for a period of 2 years with detection of anti-HCV Ab and transaminases.
Results
The prevalence of anti-HCV Ab was 32% in urémies on the waiting list. No difference was found in age (40.8 ± 12.8 years in anti-HCV-negative versus 37.3 ±13.5 in antiHCV-positive patients), M /F ratio (33/28 versus 19/10), blood units (all types of blood; 7.4± 14.2 versus 10.5 ± 15.3), provenance of kidneys (regional in 54/61 ver sus 26/29), whereas dialytic age (49.8 ±36.2 versus 96.8± 42.1 months, p
